The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Non - Small Cell Lung Cancer NSCLC
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
This is a Phase II trial evaluating the efficacy and safety of sequential pembrolizumab (200 mg every three weeks) and accelerated, dose-painted radiotherapy for patients with locally advanced NSCLC with PD-L1 expression ? 50%. Patients with PD-L1 expression < 50% will also be enrolled and treated w...
This is a Phase II trial evaluating the efficacy and safety of sequential pembrolizumab (200 mg every three weeks) and accelerated, dose-painted radiotherapy for patients with locally advanced NSCLC with PD-L1 expression ? 50%. Patients with PD-L1 expression < 50% will also be enrolled and treated with standard concurrent chemoradiotherapy to serve as a non-randomized comparison group.
Tracking Information
- NCT #
- NCT03523702
- Collaborators
- Montefiore Medical Center
- Investigators
- Principal Investigator: Nitin Ohri, MD Albert Einstein College of Medicine Principal Investigator: Balazs Halmos, MD Montefiore Medical Center
Get Well Soon